Shamburg News · 8-K filed Oct 15, 2026, 7:00 AM EDT

Tonix Pharmaceuticals Discloses Preliminary Q3 2026 TONMYA Net Revenue Estimate

TNXP · Tonix Pharmaceuticals Holding Corp.

  • Earnings
  • Materiality: high

Tonix Pharmaceuticals Holding Corp. disclosed preliminary, unaudited estimates for the quarter ended September 30, 2026, including TONMYA net revenue estimated between $14.0 million and $15.0 million. The company estimated cash and cash equivalents of approximately $162.8 million as of September 30, 2026. The company stated that financial closing procedures were not complete and actual results could differ materially.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 8.01, accession 0001493152-26-047139.

Written from the filing by Shamburg Markets. Figures are as reported by the company.